Very early neurological deterioration during intravenous thrombolysis in patients with acute ischemic stroke. 2025

Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
Stroke Center and Department of Neurology, National Taiwan University Hospital, Taiwan.

BACKGROUND Neurological deterioration within 24 h after intravenous thrombolysis with tissue plasminogen activator (tPA) is associated with poor outcomes in patients with acute ischemic stroke (AIS). This study aimed to elucidate the features of neurological deterioration specifically during tPA infusion in these patients. METHODS We analyzed patients with AIS receiving thrombolysis between January 2018 and December 2021. Very early neurological deterioration (VEND) was defined as an increase of 4 or more points in the National Institutes of Health Stroke Scale (NIHSS) score during tPA infusion. Poor functional outcome was defined as a modified Rankin Scale score of 3-6 at three months. RESULTS Among the 345 patients with AIS who received tPA, 8.4% had VEND; all of which were caused by ischemic progression. Patients with VEND had a higher prevalence of intracranial atherosclerotic disease (41% vs. 17%, P = 0.005). VEND independently predicted poor functional outcome in both groups with minor (NIHSS score <6) and non-minor (NIHSS score >6) stroke. Among patients with minor stroke, those with VEND were more likely to undergo endovascular thrombectomy (EVT) than those without (38% vs. 5%, P = 0.019). In patients receiving EVT after VEND, the NIHSS scores at 24 h, which were correlated with 3-month functional outcome, were lower in those with successful recanalization than in those without (12 ± 9 vs. 26 ± 7, P = 0.047). CONCLUSIONS VEND predicted poor functional outcomes in patients with AIS. Timely and successful recanalization using EVT potentially alleviates the negative impact of VEND on long-term outcomes.

UI MeSH Term Description Entries

Related Publications

Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
August 2025, Journal of the Formosan Medical Association = Taiwan yi zhi,
Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
December 2023, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,
Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
February 2025, World neurosurgery,
Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
January 2022, Frontiers in neurology,
Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
January 2025, Frontiers in neurology,
Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
May 2017, The neurologist,
Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
January 2024, Heliyon,
Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
January 2022, Frontiers in aging neuroscience,
Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
April 2024, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
Ying-Chi Shen, and Shin-Joe Yeh, and Chih-Hao Chen, and Sung-Chun Tang, and Li-Kai Tsai, and Jiann-Shing Jeng
January 2024, Frontiers in neuroscience,
Copied contents to your clipboard!